Male Androgenetic Alopecia

This review discusses the role of Wnt/β-catenin signaling in hair follicle regeneration and highlights recent progress in developing hair loss treatments targeting this pathway, but reports no new clinical results.

This review discusses recent genetic findings on hormonal signaling pathways in androgenetic alopecia, reporting no new study results but highlighting the need for further investigation.

This article discusses emerging therapies for androgenetic alopecia, highlighting the use of intradermal dutasteride, but it reports no new clinical findings.

This review indicates that most studies reported positive effects of platelet-rich plasma injections for treating androgenic alopecia, with no major side effects, suggesting it may be a safe alternative to Minoxidil and Finasteride.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This study observed that androgenetic alopecia significantly impacts the quality of life in males, with personal relationships being notably affected, based on Dermatology Life Quality Index and hair-specific Skindex-29 assessments.

This study found that trichoscopy revealed significant differences in certain variables, such as the brown peripilar sign and white peripilar sign, which may aid in diagnosing early and late stages of androgenetic alopecia.

This review discusses the potential role of vitamins and minerals in managing non-scarring alopecia but reports no clinical results; the authors advocate for further controlled trials to explore these relationships.

This study found that finasteride 1 mg improved hair growth in 85.7% of Korean men with androgenetic alopecia over five years, with varying effectiveness depending on the type of hair loss.

This study reports that while topical minoxidil treatment showed a response in less than 40% of men after 24 weeks, oral finasteride stopped hair loss in over 80% of patients at 12 months; perceived sexual side effects of the latter may limit its use.

This review examines complementary and alternative medicine for alopecia and finds limited support from robust clinical trials, highlighting the need for standardized studies to evaluate efficacy and safety.

This article updates Japanese guidelines for diagnosing and treating male and female-pattern hair loss, recommending specific drugs and therapies while advising against certain treatments for female-pattern hair loss.

This meta-analysis reported that platelet-rich plasma injections for androgenetic alopecia may increase hair number and thickness locally, but further studies are needed to establish their overall effectiveness.

This study found that low-level laser therapy may significantly improve androgenic alopecia in both men and women, either alone or alongside treatments like minoxidil and finasteride.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This review examines how different prostanoids and their receptors affect hair growth but provides no new clinical results; it highlights potential implications for treating hair disorders.

This abstract discusses advancements in hair transplantation technology, highlighting the role of robotics and follicular unit extraction/grafting in achieving excellent clinical outcomes, with adjuvant treatments like platelet-rich plasma, lasers, and stem cells potentially improving the durability and appearance of results.

In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.

This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.

This study reported that pathways related to apoptosis, cell proliferation, and WNT signaling might be key drivers of hair loss in androgenetic alopecia, guiding potential targets for therapy development.

In this study, researchers used genetic data from over 52,000 men to identify over 250 genetic loci associated with severe hair loss and developed a predictive algorithm for determining hair loss risk.

In this study, a topical formulation with compounds from the monoterpenoid family significantly improved hair growth indicators like anagen:telogen ratio, hair fall, and visual hair density in men and women with pattern hair loss.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This review discusses the use of finasteride for androgenetic alopecia and highlights that while it is considered safe, there is concern regarding its sexual side effects, which reverse upon discontinuation.

In this study, long-term finasteride treatment improved androgenetic alopecia in Japanese men, with younger age and less advanced disease at treatment start predicting better efficacy.

This article discusses the history taking and clinical examination process for diagnosing alopecia and outlines a diagnostic approach, noting that it reports no new clinical results.

This study suggests that dutasteride may be a viable alternative for Korean men with androgenetic alopecia who do not respond to finasteride, as it improved hair density and thickness in most participants.

This study found that topical valproic acid significantly increased hair count in male patients with moderate androgenetic alopecia compared to placebo over 24 weeks.

This study found that low-level laser treatment with the HairMax Lasercomb significantly increased terminal hair density in both men and women with pattern hair loss, with no serious adverse events reported.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

This study observed no significant relationship between trichoscopic findings and disease severity in male or female androgenetic alopecia, despite some specific patterns correlating with different severity levels in female patients.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

This article reviews the molecular mechanisms involved in androgenetic alopecia and the androgen's paradoxical role in hair growth, but reports no new experimental findings.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

This study found that topical melatonin significantly improved hair density and reduced the severity of androgenetic alopecia in men and women.

This review discusses the histopathological diagnosis of scarring and non-scarring alopecias, emphasizing the importance of adequate tissue sampling and clinical information; it reports no new empirical results.

This study found that men with Kennedy disease have a significantly lower risk of androgenetic alopecia, likely due to androgen receptor gene alterations from the disease's polyglutamine expansion.

In this study, researchers found that while the SNP rs6152 is strongly associated with androgenetic alopecia, the GGN triplet repeat is not, suggesting the causative variant is likely a non-coding one.

Runx1 is crucial for proper hair structure and development.

The study found that prolactin expressed in human scalp hair follicles acts as an autocrine modulator, inhibiting hair growth and promoting hair follicle regression, which may contribute to hair loss in hyper-prolactinemia patients.

This study found that a topical hedgehog agonist can stimulate hair growth by promoting the transition from the resting to growth phase of the hair cycle in adult mouse skin.

This study found that prolactin can induce premature catagen in both mouse and human hair follicles and suggests that targeting prolactin and TGF-β receptors may be promising for treating androgenetic alopecia.

This article reviews the clinical and diagnostic features of hair shaft disorders, emphasizing the role of structured patient assessments and the avoidance of hair trauma, but reports no new results.

This study reports that the TrichoScan method effectively measures hair growth parameters and detected significant improvements in hair counts and thickness in men with androgenetic alopecia after finasteride treatment.